Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Safinamide Methanesulfonate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Newron Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, Newron will sponsor the study and be responsible for Xadago (safinamide), development and execution, as well as leading on all related regulatory interactions. Newron and Zambon will evenly share the cost of the study.
Product Name : Xadago
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 05, 2021
Lead Product(s) : Safinamide Methanesulfonate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Newron Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Riluzole
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Cross Research S.A.
Deal Size : Inapplicable
Deal Type : Inapplicable
Riluzole Orodispersible Film Replicate Bioavailability
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 29, 2021
Lead Product(s) : Riluzole
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Cross Research S.A.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Voriconazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 18, 2020
Lead Product(s) : Voriconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cyclosporine
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
September 27, 2019
Lead Product(s) : Cyclosporine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cyclosporine
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
July 31, 2019
Lead Product(s) : Cyclosporine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Acetylcysteine
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Recipient : Johns Hopkins University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 26, 2019
Lead Product(s) : Acetylcysteine
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Recipient : Johns Hopkins University
Deal Size : Inapplicable
Deal Type : Inapplicable
Safinamide for Levodopa-induced Dyskinesia (PD-LID)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 17, 2019
Lead Product(s) : Safinamide Methanesulfonate
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 22, 2019
Lead Product(s) : Safinamide Methanesulfonate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Acetylcysteine
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 19, 2019
Lead Product(s) : Acetylcysteine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Safinamide Methanesulfonate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 19, 2019
Lead Product(s) : Safinamide Methanesulfonate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable